Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Understanding the differences between value and growth investing is essential. Learn how to choose the right approach for your goals.
24,909 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
A practical, investor-focused look at delcath (dcth) 2025 earnings prospects. We break down the catalysts, risks, and...
A year ago, a $1,000 investment in Newmont could have grown nicely as gold and miners moved. This article breaks down...
A large insider stake reduction coincided with Boise Cascade stock down, prompting questions about valuation and risk...
A high-profile insider sale at Sonic Automotive sparks questions about executive shareholdings and stock outlook. Thi...
SpaceX's IPO headlines would be enormous and tempting. This article shares the one clear message I’d tell every inves...
Mortgage rates hovering near 5% are shifting the math for buyers and investors alike. This guide breaks down what a r...
A hedge fund just trimmed a large stake in NCR Voyix, but does that spell change for ordinary investors? This guide b...
Regulators revived a stalled pipeline, prompting questions for investors in Sable Offshore. This guide breaks down wh...
As 2025 earnings season hits, savvy investors need a clear playbook for cibus (cbus) 2025 earnings. This guide breaks...
A clear guide to reading RMTI's Q1 2026 earnings call, what the numbers mean, and how to spot the catalysts that can ...
A billionaire Twilio wakes 4:30 a.m. and blends work with intense personal-finance discipline, illustrating how routi...